Androgen deprivation therapy is a lifesaving therapy used by thousands of men each year, but some patients are warning of ...

"Outside of metastatic castrate-resistant prostate cancer, both NCCN and ASCO do note that an osteoclast inhibitor (at ...

Transcript: What is androgen deprivation therapy? Alicia Morgans, M.D., MPH: Androgen deprivation therapy, sometimes called ADT or hormonal therapy, is a way of treating prostate cancer that is used ...

Androgen deprivation therapy (ADT) for prostate cancer is associated with decreased bone mineral density (BMD) in patients. This decreased BMD can lead to an increased risk of fractures and ...

During a live event, Jahan Aghalar, MD, discussed the efficacy and safety of darolutamide plus ADT in mHSPC in the ARANOTE ...

Androgen deprivation therapy is commonly used to treat prostate cancer, often on an open-ended basis for therapy of advanced prostate cancer. It is estimated that 44 percent of men with prostate ...

Outcomes are improved by concomitant androgen-deprivation therapy (ADT) with radiation therapy, but not by concomitant ADT with surgery. Luteinizing hormone–releasing hormone agonist (LHRHa; ...

Among patients with metastatic hormone-sensitive prostate cancer, the treatment combination of Nubeqa (darolutamide) and androgen deprivation therapy (ADT) has reportedly displayed positive results ...

It all began in 1941 when Huggins and Hodges 1 first described the androgen dependence of prostate cancer (PCa) by demonstrating regression of metastases by androgen deprivation. PCa is now the most ...

Cite this: Androgen Deprivation Therapy and Prostate Cancer: Bone Health, Survivorship, and Side Effects - Medscape - Jul 19, 2023. Tables. Authors and Disclosures. Authors and Disclosures ...

Recently, combined therapy with androgen deprivation therapy and androgen receptor pathway inhibitors has been recommended for metastatic hormone-sensitive prostate cancer patients.